Advances

Advances in Oncology

Novel Research Advancing Cancer Care and Treatment

Cell. The Lancet Oncology. Nature. Clinical Cancer Research.

Studies by Columbia University and Weill Cornell Medicine faculty are making headlines in oncology research, providing promising evidence for new therapies and better understanding of the origins of blood and solid tumor cancers.

In collaboration with Herbert Irving Comprehensive Cancer Center of NewYork-Presbyterian/Columbia University Irving Medical Center and Weill Cornell Medicine Meyer Cancer Center in Partnership with NewYork-Presbyterian.

Aggressive Lymphoma: Elucidating the Role of the TBL1XR1 Gene

Graphical abstract

Mutations in the TBL1XR1 gene have been identified in lymphomas, and it is known that the most aggressive B cell lymphomas frequently manifest extranodal distribution and carry somatic mutations in this poorly characterized gene. A recent multicenter study led by Weill Cornell Medicine hematology/oncology faculty exposes several ways that TBL1XR1 mutations are influencing lymphomagenesis.

Read the full article at: https://www.cell.com/cell/pdf/S0092-8674(20)30682-6.pdf

Improving Survivor Benefits for Resectable Non-Small-Cell Lung Cancer

To address the survival limitations of perioperative chemotherapy for patients with non-small-cell lung cancer presenting with resectable disease, Columbia University researchers designed a trial testing the activity of the PD-L1 inhibitor, atezolizumab, with carboplatin and nab-paclitaxel given as neoadjuvant treatment before surgical resection. Their findings suggest that this combination could be a promising neoadjuvant regimen for resectable non-small-cell lung cancer.

Read the full article at: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30140-6/fulltext

Surmounting the Sequencing Challenges of Low-Disease-Burden Monitoring

The necessary tools to track low-burden disease are lacking in many areas of oncology due in part to a combination of low tumor fraction and limited number of DNA fragments, which restricts monitoring through the prevailing deep targeted sequencing paradigm. In a recent study, Weill Cornell Medicine researchers looked at potential methods to overcome the barrier of cell free DNA abundance to optimize low-disease-burden oncology treatment.

Read the full article at: https://www.nature.com/articles/s41591-020-0915-3

Heightening the Potential of Immunotherapy for Prostate Cancer

Researchers in the NCI-designated Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center and at several sites across the country have revisited ways to enable immunotherapy to overcome the challenges posed by the prostate tumor microenvironment. Their approach incorporates androgen deprivation therapy as a component of neoadjuvant therapy prior to radical prostatectomy.

Read the full article at: https://clincancerres.aacrjournals.org/content/early/2020/05/19/1078-0432.CCR-19-3372.abstract

Refer a Patient

NewYork-Presbyterian/Columbia University Irving Medical Center
212-305-5098

NewYork-Presbyterian/Weill Cornell Medical Center
646-962-2800